{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:53:42Z","timestamp":1794376422004,"version":"4.9.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jaut.2024.103327","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T16:56:49Z","timestamp":1730393809000},"page":"103327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Identification of a novel PDC-E2 epitope in primary biliary cholangitis: Application for engineered Treg therapy"],"prefix":"10.1016","volume":"149","author":[{"given":"Ritika","family":"Tewari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Jung","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan D.","family":"McClain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleah","family":"DeSchmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravind","family":"Kancharla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhilesh K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddie A.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blaire E.","family":"Burman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Siddique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Rawlings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Cerosaletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9005-1885","authenticated-orcid":false,"given":"Jane H.","family":"Buckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2024.103327_bib1","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1034\/j.1600-0528.2002.017402.x","article-title":"Primary biliary cirrhosis: an orchestrated immune response against epithelial cells","volume":"174","author":"Gershwin","year":"2000","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jaut.2024.103327_bib2","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199405123301903","article-title":"Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group","volume":"330","author":"Poupon","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2024.103327_bib3","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1080\/14656566.2016.1218471","article-title":"Obeticholic acid for the treatment of primary biliary cholangitis","volume":"17","author":"Ali","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jaut.2024.103327_bib4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2024.103327_bib5","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0168-8278(01)00092-7","article-title":"Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'","volume":"35","author":"Lazaridis","year":"2001","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jaut.2024.103327_bib6","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.cld.2018.03.007","article-title":"Natural history of primary biliary cholangitis in the ursodeoxycholic acid era: role of scoring Systems","volume":"22","author":"Goel","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.jaut.2024.103327_bib7","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra043898","article-title":"Primary biliary cirrhosis","volume":"353","author":"Kaplan","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2024.103327_bib8","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2468-1253(19)30343-7","article-title":"Current and potential treatments for primary biliary cholangitis","volume":"5","author":"Shah","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jaut.2024.103327_bib9","unstructured":"United States Food & Drug Administration. FDA adds boxed warning to highlight correct dosing of Ocaliva (obeticholic acid) for patients with a rare chronic liver disease 02-01-2018. [cited 03\/13\/2024]; Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-adds-boxed-warning-highlight-correct-dosing-ocaliva-obeticholic-acid-patients-rare-chronic-liver."},{"key":"10.1016\/j.jaut.2024.103327_bib10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/hep4.1044","article-title":"Toward solving the etiological mystery of primary biliary cholangitis","volume":"1","author":"Tanakaa","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jaut.2024.103327_bib11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2018.10.001","article-title":"Factors associated with recurrence of primary biliary cholangitis after liver transplantation and effects on graft and patient survival","volume":"156","author":"Montano-Loza","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2024.103327_bib12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jhep.2020.09.011","article-title":"A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA","volume":"74","author":"Hirschfield","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jaut.2024.103327_bib13","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/hep.24748","article-title":"Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"55","author":"Tsuda","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2024.103327_bib14","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/hep.30099","article-title":"Rituximab is ineffective for treatment of fatigue in primary biliary cholangitis: a phase 2 randomized controlled trial","volume":"70","author":"Khanna","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2024.103327_bib15","article-title":"Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis?","volume":"14","author":"Yang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103327_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.hepres.2003.09.003","article-title":"Cellular immune response in primary biliary cirrhosis","volume":"28","author":"Kita","year":"2004","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.jaut.2024.103327_bib17","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1172\/JCI0214698","article-title":"Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis","volume":"109","author":"Kita","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2024.103327_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0090-1229(86)90049-8","article-title":"In situ characterization of the cell-surface antigens of the mononuclear cell infiltrate and bile duct epithelium in primary biliary cirrhosis","volume":"41","author":"Colucci","year":"1986","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1016\/j.jaut.2024.103327_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079580","article-title":"Association of human leukocyte antigen class II with susceptibility to primary biliary cirrhosis: a systematic review and meta-analysis","volume":"8","author":"Qin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2024.103327_bib20","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41467-019-09893-5","article-title":"Suppression of a broad spectrum of liver autoimmune pathologies by single peptide-MHC-based nanomedicines","volume":"10","author":"Umeshappa","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jaut.2024.103327_bib21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s12016-014-8419-x","article-title":"Genetics in PBC: what do the \"risk genes\" teach us?","volume":"48","author":"Hirschfield","year":"2015","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.jaut.2024.103327_bib22","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1440-1746.1991.tb00911.x","article-title":"Primary biliary cirrhosis: is there an environmental contribution?","volume":"6","author":"Triger","year":"1991","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jaut.2024.103327_bib23","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1053\/jhep.2001.29760","article-title":"The geographical distribution of primary biliary cirrhosis in a well-defined cohort","volume":"34","author":"Prince","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2024.103327_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975115","article-title":"New insights on the role of human leukocyte antigen complex in primary biliary cholangitis","volume":"13","author":"Mulinacci","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103327_bib25","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1172\/JCI4213","article-title":"Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis","volume":"102","author":"Shimoda","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2024.103327_bib26","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1056\/NEJM198905253202104","article-title":"Detection of autoantibodies to recombinant mitochondrial proteins in patients with primary biliary cirrhosis","volume":"320","author":"Van de Water","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2024.103327_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-2007-1007183","article-title":"Antimitochondrial antibodies in primary biliary cirrhosis","volume":"17","author":"Leung","year":"1997","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.jaut.2024.103327_bib28","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/jcp.53.11.813","article-title":"Autoantigens in primary biliary cirrhosis","volume":"53","author":"Jones","year":"2000","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.jaut.2024.103327_bib29","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cld.2022.06.004","article-title":"Autoantibodies in primary biliary cholangitis","volume":"26","author":"Leung","year":"2022","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.jaut.2024.103327_bib30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaut.2019.01.005","article-title":"Histologically proven AMA positive primary biliary cholangitis but normal serum alkaline phosphatase: is alkaline phosphatase truly a surrogate marker?","volume":"99","author":"Sun","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2024.103327_bib31","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2024.103327_bib32","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1002\/art.27594","article-title":"HLA-DR1001 presents \"altered-self\" peptides derived from joint-associated proteins by accepting citrulline in three of its binding pockets","volume":"62","author":"James","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2024.103327_bib33","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.4049\/jimmunol.1800723","article-title":"DRB4\u221701:01 has a distinct motif and presents a proinsulin epitope that is recognized in subjects with type 1 diabetes","volume":"201","author":"James","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2024.103327_bib34","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.151349","article-title":"Autoreactive T cell receptors with shared germline-like alpha chains in type 1 diabetes","volume":"6","author":"Linsley","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaut.2024.103327_bib35","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.171844","article-title":"GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes","volume":"9","author":"Uenishi","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaut.2024.103327_bib36","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn1716","article-title":"Pancreatic islet-specific engineered T(regs) exhibit robust antigen-specific and bystander immune suppression in type 1 diabetes models","volume":"14","author":"Yang","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jaut.2024.103327_bib37","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/art.38637","article-title":"Citrulline-specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy","volume":"66","author":"James","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2024.103327_bib38","doi-asserted-by":"crossref","first-page":"323","DOI":"10.4049\/jimmunol.1700172","article-title":"Single-cell RNA sequencing reveals expanded clones of islet antigen-reactive CD4(+) T cells in peripheral blood of subjects with type 1 diabetes","volume":"199","author":"Cerosaletti","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2024.103327_bib39","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.cell.2016.09.050","article-title":"Regulatory T cell specificity directs tolerance versus Allergy against aeroantigens in humans","volume":"167","author":"Bacher","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jaut.2024.103327_bib40","doi-asserted-by":"crossref","first-page":"5967","DOI":"10.4049\/jimmunol.172.10.5967","article-title":"Autoreactive T cells in healthy individuals","volume":"172","author":"Danke","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2024.103327_bib41","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4049\/immunohorizons.2000037","article-title":"Transcriptomic profiling of human effector and regulatory T cell subsets identifies predictive population signatures","volume":"4","author":"H\u00f6llbacher","year":"2020","journal-title":"Immunohorizons"},{"key":"10.1016\/j.jaut.2024.103327_bib42","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.cld.2022.06.003","article-title":"Immunologic responses and the pathophysiology of primary biliary cholangitis","volume":"26","author":"Chen","year":"2022","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.jaut.2024.103327_bib43","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1749-6632.2009.05133.x","article-title":"Th1 and Th17 cells: adversaries and collaborators","volume":"1183","author":"Damsker","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jaut.2024.103327_bib44","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/hep.27306","article-title":"CXCR5+ CD4+ T follicular helper cells participate in the pathogenesis of primary biliary cirrhosis","volume":"61","author":"Wang","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2024.103327_bib45","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1172\/JCI126595","article-title":"Autoreactive CD8+ T cell exhaustion distinguishes subjects with slow type 1 diabetes progression","volume":"130","author":"Wiedeman","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2024.103327_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay6422","article-title":"Gene editing to induce FOXP3 expression in human CD4(+) T cells leads to a stable regulatory phenotype and function","volume":"12","author":"Honaker","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jaut.2024.103327_bib47","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.ymthe.2023.07.016","article-title":"Dual-locus, dual-HDR editing permits efficient generation of antigen-specific regulatory T cells with robust suppressive activity","volume":"31","author":"Hunt","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jaut.2024.103327_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1166135","article-title":"Opportunities for Treg cell therapy for the treatment of human disease","volume":"14","author":"Bluestone","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103327_bib49","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltad007","article-title":"Treg-based immunotherapy for antigen-specific immune suppression and stable tolerance induction: a perspective","volume":"3","author":"Sakaguchi","year":"2023","journal-title":"Immunother Adv"},{"key":"10.1016\/j.jaut.2024.103327_bib50","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.immuni.2015.05.001","article-title":"Clonal deletion prunes but does not eliminate self-specific \u03b1\u03b2 CD8(+) T lymphocytes","volume":"42","author":"Yu","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2024.103327_bib51","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/cei.12415","article-title":"Successful immunotherapy of autoimmune cholangitis by adoptive transfer of forkhead box protein 3(+) regulatory T cells","volume":"178","author":"Tanaka","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jaut.2024.103327_bib52","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2249.2009.03898.x","article-title":"Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis: the serum cytokine profile and peripheral cell population","volume":"156","author":"Rong","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jaut.2024.103327_bib53","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.21123","article-title":"Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis","volume":"43","author":"Lan","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2024.103327_bib54","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jhep.2013.12.027","article-title":"Reduced FOXP3(+) regulatory T cells in patients with primary sclerosing cholangitis are associated with IL2RA gene polymorphisms","volume":"60","author":"Sebode","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jaut.2024.103327_bib55","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.imbio.2015.02.006","article-title":"Peak inflammation in atherosclerosis, primary biliary cirrhosis and autoimmune arthritis is counter-intuitively associated with regulatory T cell enrichment","volume":"220","author":"Garetto","year":"2015","journal-title":"Immunobiology"},{"key":"10.1016\/j.jaut.2024.103327_bib56","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/hep.28517","article-title":"Human intrahepatic regulatory T cells are functional, require IL-2 from effector cells for survival, and are susceptible to Fas ligand-mediated apoptosis","volume":"64","author":"Chen","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2024.103327_bib57","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.4049\/jimmunol.0901216","article-title":"Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver","volume":"184","author":"Oo","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2024.103327_bib58","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1002\/hep.26979","article-title":"IL-12\/Th1 and IL-23\/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy","volume":"59","author":"Yang","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2024.103327_bib59","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.coi.2007.07.020","article-title":"Th17: the third member of the effector T cell trilogy","volume":"19","author":"Bettelli","year":"2007","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jaut.2024.103327_bib60","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/hep.27552","article-title":"Follicles, germinal centers, and immune mechanisms in primary biliary cirrhosis","volume":"61","author":"Webb","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2024.103327_bib61","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/hep.24039","article-title":"Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis","volume":"53","author":"Longhi","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2024.103327_bib62","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/hep.27639","article-title":"Autoimmune hepatitis in a murine autoimmune polyendocrine syndrome type 1 model is directed against multiple autoantigens","volume":"61","author":"Hardtke-Wolenski","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2024.103327_bib63","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4049\/jimmunol.164.1.183","article-title":"Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific","volume":"164","author":"Thornton","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2024.103327_bib64","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.0105-2896.2006.00427.x","article-title":"Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease","volume":"212","author":"Sakaguchi","year":"2006","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jaut.2024.103327_bib65","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.jaci.2018.10.015","article-title":"Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: the next frontier","volume":"142","author":"Esensten","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jaut.2024.103327_bib66","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T cells and human disease","volume":"38","author":"Sakaguchi","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jaut.2024.103327_bib67","article-title":"Treg therapies revisited: tolerance beyond deletion","volume":"11","author":"Pilat","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103327_bib68","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1084\/jem.20040139","article-title":"In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes","volume":"199","author":"Tang","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2024.103327_bib69","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1084\/jem.20040180","article-title":"CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes","volume":"199","author":"Tarbell","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2024.103327_bib70","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/eji.200839073","article-title":"Curing CNS autoimmune disease with myelin-reactive Foxp3+ Treg","volume":"39","author":"Stephens","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jaut.2024.103327_bib71","doi-asserted-by":"crossref","first-page":"8140","DOI":"10.4049\/jimmunol.177.11.8140","article-title":"Gene therapy of arthritis with TCR isolated from the inflamed paw","volume":"177","author":"Fujio","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2024.103327_bib72","doi-asserted-by":"crossref","first-page":"19078","DOI":"10.1073\/pnas.0907396106","article-title":"Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis","volume":"106","author":"Wright","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaut.2024.103327_bib73","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1172\/JCI33185","article-title":"Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice","volume":"118","author":"Tsang","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2024.103327_bib74","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.4049\/jimmunol.172.3.1515","article-title":"Expression of dual TCR on DO11.10 T cells allows for ovalbumin-induced oral tolerance to prevent T cell-mediated colitis directed against unrelated enteric bacterial antigens","volume":"172","author":"Zhou","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2024.103327_bib75","doi-asserted-by":"crossref","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jaut.2024.103327_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21197015","article-title":"Treg enhancing therapies to treat autoimmune diseases","volume":"21","author":"Eggenhuizen","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jaut.2024.103327_bib77","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1053\/jhep.2000.8090","article-title":"Mimicry peptides of human PDC-E2 163-176 peptide, the immunodominant T-cell epitope of primary biliary cirrhosis","volume":"31","author":"Shimoda","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2024.103327_bib78","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1084\/jem.181.5.1835","article-title":"HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases","volume":"181","author":"Shimoda","year":"1995","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2024.103327_bib79","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0016-5085(03)00387-1","article-title":"Molecular mimicry of mitochondrial and nuclear autoantigens in primary biliary cirrhosis","volume":"124","author":"Shimoda","year":"2003","journal-title":"Gastroenterology"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841124001616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841124001616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T11:41:37Z","timestamp":1738496497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841124001616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":79,"alternative-id":["S0896841124001616"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2024.103327","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of a novel PDC-E2 epitope in primary biliary cholangitis: Application for engineered Treg therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2024.103327","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103327"}}